Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Evolving Landscape of Oral Therapies for Psoriasis
Description
April Armstrong from UCLA discusses the advancements in oral therapies for psoriasis, focusing on the promising results of small molecules targeting distinct phenotypes of the condition. She highlights the efficacy of Apremilast, particularly in Japanese populations, and emphasizes the exciting prospects of Tic 2 inhibitors like ducravacitinib, which has demonstrated significant long-term efficacy and safety in moderate to severe plaque psoriasis. With data showing substantial improvements in clinical outcomes over five years, ducravacitinib has established a strong presence in treatment protocols. New agents like icotruchinra, a peptide that inhibits interleukin-23 receptor signaling, are also showing impressive results in early studies. Furthermore, Armstrong mentions the ongoing research into other mechanisms, including those inhibiting interleukin-17 and a unique oral TNF receptor 1 inhibitor, which could offer new therapeutic avenues. Overall, the session highlights a vibrant pipeline of innovative oral therapies that may transform psoriasis management, complemented by a light-hearted dialogue on American eating contests, illustrating the cultural quirks that accompany medical advancements.
View moreConclusions
- Oral therapies are evolving as effective treatment options for psoriasis, especially in varying patient phenotypes.
- Apremilast shows promise in treating palmoplantar pustulosis, achieving significant PPPASI 50 responses among Japanese populations.
- Ducravacitinib demonstrates a favorable long-term efficacy profile, maintaining approximately 75% of patients at PASI 75 and 55% at clear or almost clear status after 5 years.
- Deucravacitinib is particularly effective for patients with mild to moderate psoriasis, showing better tolerability and effectiveness compared to biologics for those populations.
- Data from clinical studies highlight the importance of continuous assessment of oral therapies, with emphasis on PASI scores for efficacy in plaque psoriasis.
- Icotrokinra has demonstrated significant early efficacy in achieving clear skin, with higher rates of PASI 75 and 90 when compared to placebo.
- The introduction of new TYK2 inhibitors like Zasocitinib is likely to enhance target specificity and therapeutic outcomes in psoriasis treatments.
- Okubo Y, et al. EADV 2024, P2512.
- Hawkes JE et al. J Allergy Clin Immunol. 2017;140:645-653.
- Alwan W, Nestle FO. Clin Exp Rheumatol. 2015;33(5 suppl 93):S2-S6.
- Dendrou CA et al. Sci Transl Med. 2016;8:363ra149.
- Diogo D et al. PLoS One. 2015;10:e0122271.
- Li Z et al. PLoS One. 2020;15:e0225289.
- Banerjee S et al. Drugs. 2017;77:521-546.
- Strober B, et al. J Am Acad Dermatol 2023;88:40-51; 2. Armstrong A, et al. J Am Acad Dermatol 2023;88:23-37.
- Bagel J et al. EADV 2022.
- Gangolli et al. Society of Investigative Dermatology Meeting 2022.
- Papp KA, et al. AAD 2024, Late-breaking abstract. Sponsored by Alumis Inc.